Section 1: Introduction: The Value and Paradox of Second Acts in Pharmacology
The Rise of Drug Repurposing
Drug repurposing, also known as repositioning or retasking, has evolved from a series of serendipitous discoveries into a cornerstone of modern pharmaceutical development.1 The strategy involves identifying new therapeutic applications for existing drugs, including those already on the market or those previously studied but unapproved.2 Its value proposition is compelling: drug repurposing offers a more expeditious, cost-effective, and de-risked pathway to new therapies compared to the arduous
de novo drug discovery process.2
The empirical data supporting this strategic shift is significant. Repurposed drugs are generally approved for market in 3 to 12 years, a considerable acceleration compared to the 10 to 17 years typical for new chemical entities.3 The development costs are also reduced by as much as 50-60%.5 This efficiency translates into a markedly higher probability of success; approximately 30% of repurposed drug candidates gain market approval, a threefold increase over the roughly 10% success rate for novel compounds.3
This is not a niche activity but a central economic driver for the pharmaceutical industry. The global market for drug repurposing was valued at over USD 35 billion in 2024, with projections for substantial growth.7 Repurposed drugs already contribute an estimated 25% to 40% of annual pharmaceutical revenue, underscoring their profound impact.7 This powerful economic incentive fuels a continuous cycle of innovation, which in turn drives companies to explore the frontiers of intellectual property law to protect their discoveries. The high success rate and lower cost of repurposing create a strong business case, and to capture the return on this investment, companies require market exclusivity. Since the drug compound itself is often off-patent, innovators are highly motivated to develop sophisticated legal strategies—such as new use patents and complex “patent thickets”—to create that exclusivity. The commercial success of these legal strategies, as seen with blockbuster drugs, then reinforces the original business case, creating a self-perpetuating cycle where economic drivers and legal strategy mutually reinforce one another.2
The Central Legal Paradox
This commercial imperative confronts a central legal paradox. A bedrock principle of patent law is that old inventions cannot be patented again.14 An invention must be novel—bestowed upon the public for the first time by the patentee—to warrant the grant of a temporary monopoly.15 This creates a fundamental challenge: how can a company secure the market exclusivity needed to justify investing in clinical trials for a new use of a drug that may already be in the public domain?
The legal foundation for overcoming this paradox lies in a critical distinction: while the old drug itself is unpatentable, the new use of that drug may constitute a patentable invention.14 This principle allows the patent system to incentivize the discovery of valuable new applications for existing therapeutic tools. The classic case of aspirin illustrates this concept perfectly. The compound acetylsalicylic acid, patented by Bayer in 1900, has long been in the public domain and cannot be re-patented. However, a subsequent discovery of its efficacy in treating colon cancer represents a new and potentially patentable method of use.15
Drug repurposing also serves as a crucial bridge across the so-called “Valley of Death” in pharmaceutical development—the significant funding gap that often exists between promising basic academic research and commercially viable drug candidates.17 Traditional drug discovery is a long and expensive process, causing many early-stage projects to fail for lack of funding.17 By leveraging existing compounds with established safety profiles, repurposing drastically lowers the initial research and development costs and risks.2 This lower barrier to entry allows academic researchers or small biotechnology firms to generate compelling proof-of-concept data for a new use more easily, making the project a more attractive and “de-risked” investment for pharmaceutical partners and venture capitalists. In this way, repurposing builds a vital financial and developmental bridge over the traditional Valley of Death.
Report Roadmap
This report will navigate the complex landscape of patenting new uses for existing drugs. It begins by examining the core legal requirements of novelty and non-obviousness, which present the highest hurdles for repurposed drugs. It then explores the strategic crafting of patent claims and the critical differences between U.S. and European patent law. Subsequently, the report details the regulatory pathway to market approval and the formidable challenges of patent enforcement, before concluding with illustrative case studies and a strategic outlook on the future of pharmaceutical innovation.
Section 2: The Legal Gauntlet: Core Patentability Requirements for New Uses
Overview of the Four Pillars
To be granted a patent, a new use for an existing drug must satisfy the same four fundamental pillars of patentability as any other invention: it must be directed to eligible subject matter, possess utility, be novel, and be non-obvious.19 While the first two are typically straightforward for pharmaceutical inventions, the latter two—novelty and non-obviousness—represent the primary legal gauntlet that innovators must navigate.
Pillar 1: Novelty (35 U.S.C. § 102): Is the Use Genuinely New?
The novelty requirement, codified in 35 U.S.C. § 102, dictates that an invention cannot be patented if each and every one of its elements was disclosed in a single piece of “prior art”—such as a previous patent, scientific publication, or public use—before the filing date of the patent application.20 In the context of drug repurposing, the drug compound itself is, by definition, prior art. Therefore, the novelty of the invention must reside in the newly discovered method of using that compound.4
The Doctrine of Inherent Anticipation: The Hidden Threat
The most significant novelty challenge for new-use patents is the doctrine of inherent anticipation.15 Under this doctrine, a patent claim can be rejected even if the new use was not explicitly described in the prior art. If a prior art reference discloses a process or use that
necessarily or inevitably results in the newly claimed therapeutic effect, that new use is considered “inherent” in the prior art and is therefore not novel.15 This holds true even if the discoverers of the original use never recognized, appreciated, or understood this inherent property. The legal reasoning is that the public was already, even if unwittingly, receiving the benefit of the invention, and a patent cannot be granted to remove something from the public domain.15
This leads to a profound practical challenge often referred to as the “mechanism problem.” To successfully argue against an inherency rejection, an inventor may need to provide evidence that the new therapeutic effect arises from a different underlying biological mechanism than the drug’s original, known effect.14 While patent law does not formally require an inventor to disclose the mechanism of action, in the context of repurposing, understanding and elucidating the mechanism can become the dispositive factor in establishing novelty. The core of the novelty inquiry is identity, and determining whether the identical inherent characteristic is responsible for both the old and new uses often requires a deep dive into the underlying science.14
Pillar 2: Non-Obviousness (35 U.S.C. § 103): The Inventive Leap
Beyond being new, an invention must also be non-obvious. This is frequently the highest and most subjective hurdle to clear in obtaining a patent for a repurposed drug.22 Codified in 35 U.S.C. § 103, this requirement states that a patent cannot be granted if the differences between the invention and the prior art are such that the invention as a whole would have been obvious to a “Person Having Ordinary Skill in the Art” (PHOSITA) at the time the invention was made.20
The modern standard for obviousness was shaped by the U.S. Supreme Court’s decision in KSR International Co. v. Teleflex Inc., which held that an invention may be obvious if it combines familiar elements according to known methods to yield predictable results.21 For a repurposed drug, the central question becomes: would a skilled pharmacologist or clinician, knowing the drug’s known properties and mechanism of action, have had a reason or motivation to test it for the new disease with a reasonable expectation of success?.4
To overcome an obviousness rejection, an inventor can present several types of evidence. This includes showing that the prior art “teaches away” from the new use (i.e., suggests it would not work), demonstrating that the drug produced unexpected or synergistic results, or proving that the invention fulfilled a long-felt but previously unsolved medical need.20
The legal doctrine of inherency can create a practical “Catch-22” for innovators. To prove novelty against an inherency rejection, an applicant might need to present evidence of a new biological mechanism. However, the very act of elucidating a mechanism related to a known drug could then be used by a patent examiner to argue that the new use was obvious. For instance, an applicant might show that their new use for Disease Y operates via Mechanism B, distinct from the known Mechanism A for the old use in Disease Z, thus establishing novelty. The examiner could then counter with an obviousness rejection, arguing that a skilled person, knowing the drug affects Mechanism A, would have found it obvious to test its effect on the closely related Mechanism B to treat Disease Y. The innovator is thus caught in a difficult position where the evidence required to defeat a novelty rejection can become the basis for an obviousness rejection, demanding a delicate strategic balance in how evidence is presented.
Pillar 3: Utility (35 U.S.C. § 101): Is the Use Useful?
The final requirement is utility. An invention must possess a specific, substantial, and credible use to be patentable.19 In the pharmaceutical context, this is generally a low bar, as treating a human disease is a clear and widely accepted utility. The patent application must simply provide sufficient evidence to support the assertion that the drug is effective for the new indication. This can be in the form of preclinical data or a plausible scientific rationale; advanced human clinical trial data is not typically required at the time of filing the patent application.1
A systemic issue in the examination of new-use patents is the allocation of the burden of proof, which often favors the applicant. The patent examiner must first establish a prima facie case of unpatentability, which can be challenging when dealing with complex biology and the subtle doctrine of inherency.15 This information deficit for the examiner can lead to what legal scholar Sean Seymore terms a “pro-applicant bias” and “perfunctory views of novelty,” potentially resulting in the issuance of patents for uses that are not truly novel.14 The current system may systematically undervalue the “identity” component of novelty in favor of superficial differences in disease indication. A proposed solution to correct this imbalance is to shift the burden of proof, requiring the applicant—the party with superior access to information—to affirmatively provide evidence of mechanistic distinction.15
Section 3: The Armory of Protection: Crafting Claims for Repurposed Drugs
Beyond the Compound: The Centrality of Method Claims
Since the active pharmaceutical ingredient of a repurposed drug is often off-patent or in the public domain, patent protection cannot be obtained for the compound itself. Instead, innovators must seek protection for its new application. The primary legal instrument for this purpose is the Method of Treatment (MOT) patent, also known as a Method of Use (MoU) patent.1 The claims in such a patent are directed not to the drug, but to the act of using it for a new therapeutic purpose. A typical claim is structured as follows: “A method of treating disease X, comprising administering a therapeutically effective amount of drug Y”.1
Building a “Patent Thicket”: A Multi-Layered Defense
Relying on a single MOT patent is often a precarious strategy, as these patents can be challenging to enforce.12 A more robust and sophisticated intellectual property strategy involves the creation of a “patent thicket”—a dense, overlapping web of various types of patents that collectively create formidable barriers to entry for generic competitors.12 This multi-layered defense can include:
New Formulations: A powerful strategy is to patent a new formulation or delivery system for the drug, such as an extended-release tablet, a topical cream, an injectable depot, or a nanoparticle-based carrier.4 If this new formulation provides a distinct advantage for the new indication (e.g., improved bioavailability, reduced side effects, better patient compliance), it can be patented as a new product. This shifts the protection from a method back to a tangible composition of matter, which is generally stronger and easier to enforce.
New Dosage Regimens: Claims can be directed to a specific and non-obvious dosing schedule that is found to be critical for the new use’s safety and efficacy profile. This could involve a particular daily frequency, a loading dose followed by a maintenance dose, or a specific titration schedule that differs from the original use.4
New Combinations: Another effective approach is to patent the use of the repurposed drug in combination with one or more other active agents.4 If the combination demonstrates unexpected synergistic effects—meaning the therapeutic benefit is greater than the sum of the individual drugs’ effects—it can form the basis of a strong patent.
New Patient Populations: Protection can also be sought for the use of the drug in a specific, well-defined, and physiologically distinct patient subgroup.29 For example, if it is discovered that patients with a particular genetic biomarker respond exceptionally well to the drug for the new indication, a patent can be filed claiming the method of treating that specific population.
These different types of secondary patents work in a symbiotic relationship to overcome the inherent enforcement weaknesses of a standalone MOT patent. A pure MOT patent is vulnerable to “off-label” prescribing, where a generic company can launch its product with a “skinny label” for an unpatented use, knowing that physicians may prescribe it for the patented use.1 However, this loophole can be closed if the new patented use requires a
specific formulation (e.g., an extended-release tablet) or a specific dosage strength that is not available for the original indication. In such a case, a generic manufacturer cannot easily provide a substitutable product without directly infringing the new formulation or dosage patent. Thus, formulation and dosage patents are not merely tools for extending patent life; they are critical strategic instruments that can transform a difficult-to-enforce method patent into a much more robust and enforceable product patent.
The practice of filing these secondary patents is at the heart of a contentious policy debate. Critics often label this strategy as “evergreening,” arguing that it involves making trivial modifications to a drug solely to extend a sales monopoly and block lower-cost generic competition.13 From this perspective, it is a way to “game the system.” In contrast, the pharmaceutical industry frames the same practice as “lifecycle management,” contending that it protects legitimate, valuable, and often costly follow-on innovation.26 The legitimacy of the strategy ultimately hinges on the
clinical value of the subsequent invention. A patent on a new formulation that offers no tangible patient benefit is more akin to evergreening. Conversely, a patent on a new formulation that significantly improves patient compliance, reduces side effects, or enhances efficacy represents legitimate lifecycle management. This distinction is not purely legal but also medical and ethical, forming the crux of the public policy debate surrounding drug patents.
Section 4: A Tale of Two Systems: Navigating U.S. and European Patent Law
Jurisdictional Divergence is Key
A global patent strategy for a repurposed drug cannot be one-size-fits-all. The legal frameworks of the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) are founded on fundamentally different principles regarding the patentability of medical treatments, necessitating distinct approaches to claim drafting and enforcement.32
The U.S. Approach (USPTO): Direct Method of Treatment Claims
The United States permits patent claims that are directed to the act of treating a human patient. This “method of treatment” (MOT) format is considered a straightforward and powerful tool for innovators.16 A typical claim in the U.S. would read:
“A method of treating colon cancer, comprising administering an effective amount of aspirin to a patient in need thereof.” 16
This claim directly protects the therapeutic action itself.
The European Approach (EPO): A Prohibition and a Workaround
In stark contrast, the European Patent Convention (EPC) explicitly prohibits the patenting of “methods for treatment of the human or animal body by surgery or therapy” under Article 53(c).29 This exclusion is rooted in a long-standing public policy and ethical principle that medical practitioners should be free to use their skills to treat patients without the fear of infringing a patent.34
To ensure that medical innovations can still be protected, the EPC provides a specific and elegant workaround. Article 54(5) of the EPC allows a known substance or composition to be patented for a specific, new medical use, provided that use is novel and demonstrates an inventive step.29 The claim is not directed to the method, but rather to the product itself, limited by its intended new purpose. This is known as a “purpose-limited product claim.” The standard format is:
“Aspirin for use in a method of treating colon cancer.” 16
This format, often referred to as the “EPC 2000 format,” protects the substance when it is intended for that specific new therapeutic application.32 This protection is strictly limited to a “substance or composition” and cannot be used to protect a new use of a medical device.29 The new use can be the treatment of an entirely new disease or a novel therapeutic method for a previously known disease, such as a new dosage regimen or a new patient group.29
The difference in claim format between the U.S. and Europe is not merely semantic; it reflects a deep philosophical divergence. The U.S. system patents the physician’s action, while the European system patents the product intended for that action. This has profound strategic implications for enforcement. In the U.S., the direct infringer is technically the doctor or patient performing the method, with the manufacturer being liable for inducing that infringement. In Europe, the infringer is the party making or selling the drug for the patented purpose. This fundamental difference in who is considered the infringer alters the entire enforcement strategy in each jurisdiction.
Furthermore, the EPO’s strict limitation of these claims to a “substance or composition” creates a potential gap in protection for certain types of innovation.29 For example, if an innovator discovers a novel and inventive therapeutic method that involves using a known medical device (like a specific type of catheter) in a new way, they face a challenge in Europe. A direct method claim is barred by Article 53(c), and a purpose-limited product claim under Article 54(5) is unavailable because a catheter is a device, not a substance.39 This legal constraint could disincentivize certain medical innovations in Europe compared to the U.S., particularly those at the intersection of devices and therapeutic methods.
Table 1: Comparison of U.S. and European Frameworks for Second Medical Use Patents
Feature
United States (USPTO)
Europe (EPO)
Legal Basis
35 U.S.C. §§ 101, 102, 103
European Patent Convention (EPC) Arts. 53(c), 54(5), 82
Core Principle
Methods of treatment are patentable subject matter.
Methods of treatment are explicitly excluded from patentability for ethical reasons.
Allowable Claim Format
Method of Treatment (MOT) Claim: “A method of treating, comprising administering…”
Purpose-Limited Product Claim: ” for use in a method of treating.”
What is Protected?
The act of performing the therapeutic method.
The substance or composition when intended for the specified new use.
Key Limitations
Subject to challenges of inherent anticipation and obviousness. Enforcement can be complex due to off-label use.
Protection is limited to a “substance or composition,” not devices. The new use must be novel and inventive.
Example
“A method of treating colon cancer, comprising administering an effective amount of aspirin…” 16
“Aspirin for use in a method of treating colon cancer.” 16
Strategic Implication
Focus on proving inducement of infringement by manufacturers. Broader potential scope to cover actions.
Focus on proving the product is being marketed/sold for the patented purpose. Claim drafting must be precise to fit the “substance or composition” definition.
Section 5: From Patent to Patient: The Regulatory Pathway
The FDA’s Role
Securing a patent grants the right to exclude others from practicing an invention; it does not grant the right to market a drug. That authority rests with regulatory bodies like the U.S. Food and Drug Administration (FDA). For repurposed drugs, a specialized regulatory pathway exists that is designed to streamline the approval process.
The 505(b)(2) New Drug Application (NDA): A Hybrid Approach
The 505(b)(2) pathway is a type of New Drug Application (NDA) that serves as a hybrid between a full NDA for a new chemical entity (a 505(b)(1) application) and an Abbreviated New Drug Application (ANDA) for a generic drug (a 505(j) application).40 Its defining feature is that it allows a sponsor to rely, at least in part, on the FDA’s previous findings of safety and effectiveness for a previously approved drug—known as the “reference listed drug” (RLD)—or on data available in the published scientific literature.40
This pathway is exceptionally well-suited for repurposed drugs. By leveraging existing data, sponsors can avoid the need to conduct a full suite of duplicative preclinical and early-phase clinical safety studies, which are the most time-consuming and expensive parts of drug development. This dramatically reduces the cost and accelerates the timeline to market approval.40 The 505(b)(2) pathway is the ideal regulatory route for drugs with new indications, new formulations, new dosage forms, or new combinations of previously approved drugs.40
The 505(b)(2) pathway is, in effect, the commercial engine of drug repurposing. Without the ability to rely on existing data, the economic model for most repurposing projects would collapse. The cost to develop a drug de novo can exceed $1 billion, an investment that would be impossible to justify for an off-patent compound that would face immediate generic competition.18 The 505(b)(2) pathway lowers this financial barrier by allowing developers to bypass most of these costs, making the projects commercially viable and attractive to investors. This regulatory provision is the critical linchpin that connects the scientific discovery of a new use to a viable commercial product.40
Market Exclusivity as a Patent Supplement
In addition to patent protection, products approved via the 505(b)(2) pathway can be granted their own periods of market exclusivity by the FDA. These regulatory exclusivities are distinct from patents and can provide a valuable layer of protection, especially for drugs with weak or expired patent coverage.40 Key types of exclusivity include:
Three-Year “New Use” Exclusivity: Granted for a new indication or other significant change that required new clinical investigations to obtain approval.
Five-Year New Chemical Entity (NCE) Exclusivity: Although less common for repurposed drugs, it can sometimes be obtained.
Seven-Year Orphan Drug Exclusivity (ODE): This is a particularly powerful incentive granted to drugs developed to treat rare diseases (affecting fewer than 200,000 people in the U.S.). ODE prevents the FDA from approving another application for the same drug for the same rare disease for seven years, providing a strong monopoly even for an off-patent compound.12
Successful commercialization requires the meticulous alignment of patent prosecution and regulatory strategy. These two processes run on different timelines and have different data requirements. A failure to coordinate them can be catastrophic. For instance, a company might file a patent application early based on promising pre-clinical data to secure an early priority date. However, during the subsequent, longer process of generating clinical data for the FDA, the optimal dosing regimen or formulation might change. If these changes are substantial, the final approved product may no longer be covered by the claims of the original patent. The company could be left with a valid patent that does not protect its own marketed product, creating a fatal commercial vulnerability. This illustrates that intellectual property and regulatory strategies must be co-developed and dynamically adjusted, not pursued as separate, sequential tasks.
Section 6: The Post-Grant Battlefield: Enforcement, Infringement, and “Skinny Labels”
The Enforcement Conundrum
Obtaining a new-use patent is only the first step; enforcing it against infringement presents a unique and formidable set of challenges that are central to the commercial viability of any drug repurposing venture.1
Off-Label Use and Induced Infringement
The primary enforcement obstacle is the common medical practice of “off-label” prescribing. Physicians have the legal right and discretion to prescribe an FDA-approved drug for any indication they deem medically appropriate, even if that use is not included in the drug’s official FDA-approved labeling.48 When a generic version of a drug becomes available for an unpatented indication, a physician can legally prescribe that low-cost generic for a different, still-patented use. In this scenario, the physician and the patient are technically direct infringers of the new-use patent. However, suing doctors and patients is commercially unfeasible and ethically problematic.1
Consequently, the patent holder’s only viable legal recourse is to sue the generic manufacturer under the doctrine of “induced infringement,” codified in 35 U.S.C. § 271(b).49 To win such a case, the patent holder must prove that the generic company took active, affirmative steps to encourage or promote the infringing off-label use by physicians, with the specific intent to cause the infringement.49
The “Skinny Label” Gambit
Generic manufacturers have a powerful tool to counter allegations of inducement: the “skinny label.” The Hatch-Waxman Act allows a generic company to seek FDA approval for only the unpatented uses of a drug, explicitly “carving out” any indications that are still protected by patents from its official label and prescribing information.30 The generic is thus marketed with a “skinny” label that only lists the non-patented uses.
This creates a complex legal battleground. The core question is whether a generic company, despite using a skinny label, can still be held liable for inducing infringement. Brand-name manufacturers argue that by marketing a bioequivalent generic product, the company knows and intends for it to be used interchangeably for all indications, including the patented one, especially given that pharmacists often automatically substitute a generic for a brand-name prescription.49 Landmark court cases, such as
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. and H. Lundbeck A/S v. Lupin Ltd., have grappled with this issue. The courts have established that the analysis depends on the totality of the defendant’s conduct. Evidence of inducement can be found in a generic company’s press releases, advertising materials, product catalogs, and even the way safety data is presented on the label if it implicitly suggests the patented use.30 While the
Lundbeck decision affirmed that a properly crafted skinny label, by itself, is not sufficient evidence of inducement, the line between permissible marketing and active inducement remains a heavily litigated and fact-intensive gray area.49
The legal battles over skinny labels represent a fundamental conflict between two congressional mandates. On one hand, the Patent Act is designed to grant a period of exclusivity to incentivize innovation, such as the discovery of a new medical use. On the other, the Hatch-Waxman Act was enacted to accelerate the market entry of low-cost generic drugs to reduce healthcare costs.41 The skinny label provision is the mechanism by which the law attempts to reconcile these competing goals. However, the realities of medical practice (off-label prescribing) and pharmacy practice (automatic generic substitution) cause these two public policies to collide. The resulting high-stakes litigation is essentially the judicial system being tasked with drawing a line between these competing statutory objectives, a task made difficult by the unresolved tension in the law itself.
At its core, the enforcement problem is driven by an information asymmetry. The patent holder’s ability to enforce its rights is crippled by the fact that it cannot easily determine why a physician prescribed a generic drug.51 A prescription for a generic is an ambiguous event; it could be for a legitimate, unpatented use or for an infringing, patented use. The crucial information about the intended use is held by the physician and is protected by patient privacy. This information gap is the fundamental barrier to enforcement. This reframes the issue from a purely legal problem to a data and systems problem, suggesting that a potential solution might lie not in further tweaking patent law, but in creating a mechanism to bridge the information gap between the healthcare system and the intellectual property system, for instance, by leveraging data from health insurers’ prior authorization processes.51
Section 7: Case Studies in Drug Repurposing
Real-world examples powerfully illustrate the scientific, legal, and commercial dynamics of drug repurposing. The journeys of sildenafil, finasteride, and thalidomide showcase the spectrum of discovery and the tailored patent strategies required for success.
Case Study 1: Sildenafil (Viagra) – The Serendipitous Blockbuster
Origin: Sildenafil was originally synthesized and developed by Pfizer in the early 1990s as a potential treatment for hypertension (high blood pressure) and angina (chest pain). Its mechanism of action is the inhibition of an enzyme known as phosphodiesterase type 5 (PDE5).52
Discovery: The drug’s destiny changed during Phase I clinical trials. While it showed only modest effects on angina, an observant nurse reported a frequent and unexpected side effect among male volunteers: they were experiencing significant penile erections.52
Repurposing & Patent Strategy: Recognizing the immense commercial potential of this accidental discovery, Pfizer astutely pivoted its entire development strategy. The company filed new patents protecting the method of using sildenafil to treat erectile dysfunction (ED). Launched in 1998 as Viagra, it became one of the most successful and widely recognized drugs in history, a quintessential example of serendipity leading to a blockbuster product.52
Further Repurposing: In a remarkable full-circle development, sildenafil was later re-investigated for its original cardiovascular purpose. In 2005, the FDA approved the same compound under the brand name Revatio for the treatment of pulmonary arterial hypertension, a serious lung condition. This demonstrated a second successful repurposing of the same molecule, solidifying its legacy.52
Case Study 2: Finasteride (Propecia) – A Strategy of Dose and Formulation
Origin: Finasteride was developed by Merck and approved by the FDA in 1992 under the brand name Proscar. At a dose of 5 mg, it was used to treat benign prostatic hyperplasia (BPH), or an enlarged prostate. Its mechanism involves inhibiting the enzyme Type II 5-alpha reductase, which prevents the conversion of testosterone to the more potent androgen dihydrotestosterone (DHT).57
Discovery: Similar to sildenafil, a key side effect was noted during the clinical trials for Proscar: many men experienced a slowing of hair loss and, in some cases, significant hair regrowth.57
Repurposing & Patent Strategy: Merck initiated a new development program specifically for androgenetic alopecia (male pattern baldness). This research determined that a much lower dose—1 mg—was effective for treating hair loss. Merck then patented this new, lower-dose formulation and method of use. In 1997, it was approved by the FDA as Propecia.57 This case is a classic example of a “lifecycle management” strategy, where a new dosage form and indication were patented to create a distinct, commercially successful product for a new patient population.61
Case Study 3: Thalidomide (Thalomid) – Redemption and Renaissance
Origin: Thalidomide has one of the most tragic histories in modern medicine. Marketed in the late 1950s as a sedative and treatment for morning sickness, it was discovered to be a potent teratogen, causing thousands of catastrophic birth defects worldwide.62
Discovery: The drug was withdrawn from the market in disgrace. However, scientific research continued, and decades later, scientists discovered that thalidomide possessed powerful anti-angiogenic (inhibiting blood vessel growth) and immunomodulatory properties, which are crucial mechanisms in fighting certain cancers.63
Repurposing & Patent Strategy: This research led to clinical trials that demonstrated significant efficacy against multiple myeloma, a cancer of plasma cells. The new method of using thalidomide to treat myeloma was patented. In 2006, the FDA approved the drug under the brand name Thalomid for this indication, but under a strict Risk Evaluation and Mitigation Strategy (REMS) program to prevent any exposure to pregnant women.63 The redemption of thalidomide not only provided a life-saving treatment but also gave rise to a new class of more potent and safer immunomodulatory drugs, such as lenalidomide (Revlimid) and pomalidomide (Pomalyst), which have become standards of care in hematology.64
These cases reveal that the “discovery” of a new use exists on a spectrum. Sildenafil’s repurposing was born from pure serendipity in a clinical trial. Finasteride’s was also an observed side effect, but because its underlying mechanism (DHT reduction) was understood, the link to hair loss was more logical, and the subsequent development of a lower-dose pill was a targeted and deliberate strategy. Thalidomide’s revival was the most scientifically intensive, stemming from decades of fundamental research into its biological properties long after its withdrawal. This implies that a comprehensive corporate repurposing strategy should be both opportunistic—closely monitoring clinical trial data for unexpected signals—and systematic, using modern computational methods to screen vast libraries of old compounds against new biological targets.
The patent strategy in each case directly mirrored the nature of the scientific innovation. For sildenafil, the core innovation was a completely new use, making a Method of Use patent the primary form of protection. For finasteride, the innovation was twofold: the new use for hair loss and the discovery that a different, lower dose was optimal. This enabled Merck to obtain a patent on a new dosage strength, a stronger form of protection that created a distinct product. For thalidomide, the new-use patent was the crucial first step in a much longer lifecycle strategy that ultimately led to the development of new, patentable derivative molecules with improved properties, demonstrating how repurposing can be the starting point for a new wave of de novo discovery.
Section 8: Strategic Conclusion: The Future of Pharmaceutical Innovation
Synthesis of Key Findings
The ability to patent a new use for an existing drug is a legally complex but commercially vital component of the modern pharmaceutical landscape. This analysis has shown that while the drug compound itself may be old, a new method of using it can be a patentable invention, provided it clears the high bars of novelty and non-obviousness. Success requires a sophisticated, multi-layered intellectual property strategy that moves beyond simple method-of-use claims to build a “patent thicket” of formulation, dosage, and combination patents. This IP strategy must be meticulously aligned with a tailored regulatory approach, typically leveraging the FDA’s 505(b)(2) pathway, and must anticipate the formidable post-grant enforcement challenges posed by off-label prescribing and the “skinny label” defense.
The Role of Emerging Technologies
The future of drug repurposing is being reshaped by the convergence of big data and artificial intelligence. Historically reliant on serendipity or painstaking laboratory research, the field is rapidly transitioning into a data-driven science. Computational biology and machine learning algorithms can now systematically screen vast databases of existing drugs against complex models of disease biology, identifying non-obvious drug-disease connections with a speed and precision previously unimaginable.1 This technological shift not only accelerates the discovery process but also strengthens the legal position of innovators. By uncovering therapeutic links through complex and unexpected biological pathways, these AI-driven discoveries provide a powerful argument against obviousness rejections during patent prosecution.
The Enduring Policy Debate
The practice of patenting new uses lies at the nexus of an enduring policy debate. On one side is the imperative to incentivize valuable follow-on innovation that can lead to life-saving treatments for new diseases. On the other is the concern that these secondary patents can be used for anti-competitive “evergreening,” extending drug monopolies with trivial modifications to delay the entry of lower-cost generics.27 The resolution of this tension does not lie in abandoning new-use patents, but rather in the rigorous and consistent application of the core patentability standards. A patent system that strictly enforces the requirements for novelty and non-obviousness, and that scrutinizes the true clinical value of a follow-on invention, can effectively distinguish between genuine innovation and mere market maneuvering.
Final Recommendations
Based on this comprehensive analysis, the following strategic recommendations are offered:
For Innovators: A proactive and integrated strategy is paramount. Intellectual property protection should be considered from the earliest stages of research. Adopt a multi-layered approach, planning for a portfolio of MOT, formulation, dosage, and combination patents. Critically, patent and regulatory strategies must be developed in parallel, not sequentially, to ensure the final approved product is fully protected by the issued patents.
For Investors: Due diligence for a drug repurposing venture must extend far beyond the scientific merit. A thorough analysis of the intellectual property landscape is essential, including an assessment of the strength and breadth of the patent claims, the specific jurisdictional nuances between the U.S. and Europe, and a realistic evaluation of the enforcement risks, particularly those associated with off-label use and the skinny label defense.
For Policymakers: The legal framework must continue to evolve to balance innovation and access. Consideration should be given to legislative or judicial clarifications that could bring greater predictability to the standards for induced infringement in the skinny label context. Furthermore, exploring novel, data-driven solutions to the enforcement problem—such as creating secure mechanisms for patent holders to access anonymized prescribing data from insurers—could more directly address the information asymmetry at the heart of the issue, thereby strengthening the incentives for valuable drug repurposing without impeding legitimate generic competition.
